Amneal Pharmaceuticals Hits New 52-Week High at $18.81

Amneal Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 18.81 on July 28, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 173.87% rise over the past year, significantly outpacing the S&P 500's performance of 16.26% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology sector, Amneal Pharmaceuticals boasts a market capitalization of USD 3,728 million. The stock's price-to-earnings (P/E) ratio stands at 22.00, indicating its valuation relative to earnings. However, the company currently does not offer a dividend yield, and its debt-to-equity ratio is reported at -32.15, suggesting a unique financial structure. The stock's previous 52-week low was recorded at USD 7.67, highlighting the substantial growth it has experienced. This upward trend in Amneal Pharmaceuticals' stock price underscores its evolving market position within the competitive landscape of the pharmaceuticals industry.